zaprinast and indolidan

zaprinast has been researched along with indolidan* in 1 studies

Other Studies

1 other study(ies) available for zaprinast and indolidan

ArticleYear
Biochemical and pharmacological characterization of cyclic nucleotide phosphodiesterase in airway epithelium.
    Molecular and cellular biochemistry, 1994, Nov-23, Volume: 140, Issue:2

    According to their respective elution order, specificity for cAMP and cGMP, their sensitivity to calmodulin, and their modulation by cGMP and rolipram, four cyclic nucleotide phosphodiesterases (PDE) were separated from the cytosol: PDE I (calmodulin-sensitive), PDE II (stimulated by cGMP, PDE IV (cGMP specific-PDE and inhibited by rolipram) and PDE V (cGMP specific). PDE IV (Km = 1.4 microM) was competitively inhibited by rolipram (Ki = 1.2 microM) whereas PDE V (Km = 0.83 microM) was competitively inhibited by zaprinast in the mumolar range (Ki = 0.12 microM). Moreover the microsomal fraction contained three PDE isoforms: PDE II, PDE III (inhibited by cGMP or indolidan) and PDE IV. These results show that cAMP degradation in cytosolic and membrane fractions is modulated by cGMP and selectively inhibited by rolipram and, in addition, by indolidan in membrane fractions.

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Cattle; Cell Membrane; Cyclic GMP; Cytosol; Egtazic Acid; Epithelium; Indoles; Isoenzymes; Kinetics; Microsomes; Oxindoles; Phosphodiesterase Inhibitors; Purinones; Pyridazines; Pyrrolidinones; Rolipram; Substrate Specificity; Trachea

1994